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MicroRNA (miRNA) have gained widespread attention for their role in diverse vascular processes including angiogenesis,
apoptosis, proliferation, andmigration. Despite great understanding of miRNA expression and function, knowledge of long
noncoding RNA (lncRNA)molecular mechanisms still remains limited. The influence ofmiRNA on lncRNA function, and the
converse, is now beginning to emerge. lncRNAmay regulate miRNA function by acting as endogenous sponges to regulate
gene expression andmiRNA have been shown to bind and regulate lncRNA stability. A detailed understanding of the
molecular and cellular effects of lncRNA-miRNA-mediated interactions in vascular pathophysiology could pave the way for
new diagnostic markers and therapeutic approaches, but first there is a requirement for a more detailed understanding of
the impact of such regulatory networks.
It is well established that vascular diseases such as atherosclerosis
and ischemic heart disease are among the leading causes of
healthcare burden, morbidity, and mortality in Western society.1
Endothelial injury, a phenotypic alteration in endothelial func-
tion, appears to be one of the initiating factors of vascular disease.
Pathological changes are accompanied by proinflammatory cyto-
kines and growth factors and reduction in antithrombogenic
agents, leading to a reduction in endothelial integrity. Together
the diverse range of cytokines and growth factors are believed to
initiate smooth muscle cell proliferation and migration leading to
vessel disease and occlusion. Very few systemic therapies exist to
treat vascular stenosis, thus new therapies are urgently required.
One such mechanism may be through the utilization of noncod-
ing RNA. Both microRNA (miRNA) and long noncoding RNA
(lncRNA) have been implicated in pathological processes
involved in vascular disease. Interestingly, direct binding of
lncRNA and miRNA and subsequent alteration in the function
of these molecules has now been discovered.2 Here we review
the abnormalities in cellular functioning of vascular endothelial
and smooth muscle cells, key interactions between novel miRNA
and lncRNA, and how these interactions may be utilized
therapeutically.
VASCULAR ENDOTHELIAL CELLS
The vascular endothelium is no longer thought of as an inert bar-
rier, but a critical regulator of vascular homeostasis. It is widely
accepted that endothelial cells maintain vascular integrity and
prevent thrombosis following the secretion of a number of
antithrombotic mediators, such as prostaglandins and nitric oxide
(NO),3,4 that prevent platelet activation and inflammatory cell
infiltration. Although endothelial activation and initiation of the
thrombotic cascade plays a prominent role in wound healing,
prolonged periods of endothelial dysfunction and activation can
lead to the initiation and progression of a number of vascular
pathologies, such as in stent restenosis and intimal formation in
response to vein grafting. A number of studies have demonstrated
that acute injury or exposure to oxidized lipids can induce activa-
tion of the inflammatory nuclear transcription factor jB (NF-
jB), resulting in increased expression of inflammatory cytokines
such as interleukin (IL-1), tumor necrosis factor alpha (TNF-a),
and monocyte chemoattractant protein-1 (MCP-1), which
upregulate a number of adhesion molecules that enhance leuko-
cyte recruitment and adhesion to the arterial wall (reviewed in
more detail by Libby et al.5). Indeed, a number of studies in
genetically modified mice have demonstrated that loss of TNF-a
or IL-1 or their receptors substantially reduces neointimal forma-
tion following ligation injury.6,7 In concordance, IL-1 receptor
antagonist (IL-1Ra)-deficient mice develop increased neointimal
formation in response to injury,8 whereas IL-1Ra administration
to mice maintained on an atherogenic background reduces fatty
lesion formation.9 Figure 1 highlights the key initiating steps in
endothelial dysfunction for several vascular pathologies. Endothe-
lial denudation and medial wall injury are the initial effects
caused by balloon and/or stent deployment following percutane-
ous coronary intervention (PCI). Increased sheer stress and
genetic susceptibility promotes endothelial injury in the setting of
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pulmonary arterial hypertension (PAH), while well-known cardi-
ovascular risk factors initiate the vascular injury and “repair proc-
ess” leading to atherosclerosis.
ROLE OF SMOOTH MUSCLE CELLS AND GROWTH FACTORS
The fully differentiated vascular smooth muscle cells (VSMC) of
human vessels are typically quiescent and are characterized by a
low proliferative index. However, unlike many mature cells in the
adult body, they do not terminally differentiate and retain
remarkable plasticity. They have the ability to switch between a
differentiated and quiescent contractile state and a highly migra-
tory and proliferative synthetic state.10 This ultimately requires
activation of “defined” gene networks (reviewed in detail in a
recent review by McDonald et al.11).
In addition to inflammatory cytokines, a series of eminent
studies by Reidy and co-workers determined that a number of
growth factors, basic fibroblast growth factor (bFGF) and
platelet-derived growth factor (PDGF), are potent mitogens and
chemoattractants that stimulate neointimal formation following
injury. In brief, in the rat carotid balloon injury model, depletion
of platelets or pretreatment with antibodies to PDGF attenuated
neointimal formation.12,13 These studies demonstrated that inhi-
bition of PDGF selectively reduced intimal VSMC migration
without affecting early medial VSMC proliferation. In contrast,
pretreatment with antibodies to bFGF inhibited early medial
proliferation, but not later intimal migration and proliferation of
VSMC.14 Furthermore, systemic infusion of bFGF increased inti-
mal hyperplasia following balloon injury in rats.15 However, infu-
sion of PDGF or bFGF did not induce intimal lesion formation
in the absence of injury. Taken together, these observations sug-
gest that injury does more than simply release growth factors.
Release of other mediators has been considered as an essential
cofactor for intimal cell formation. Indeed, models of balloon
injury and vein grafting have documented an elevation of extrac-
ellular proteases, including plasminogen activator16 and matrix
metalloproteinases, following balloon injury or vein grafting.17–19
Animal models suggest that cytokines and proteases released
from activated leukocytes initiate protease secretion and activa-
tion, resulting in a switch in SMC phenotype, from a differenti-
ated and contractile phenotype to a proliferative and synthetic
state, resulting in adventitial and medial remodeling.
NONCODING RNA
Our current knowledge of the role of RNA in gene regulation
has emerged from recent advances in genomic techniques, allow-
ing us to study full transcriptomes of organisms. These technical
advances have revealed that mammals produce thousands of non-
coding RNA and evidence suggests that in mammals noncoding
RNA constitute a substantial majority of transcripts within the
genome. It has been suggested that as much as 98% of the human
genome encodes for noncoding transcripts, and speculate that
differences in organism complexity may arise from the vast differ-
ences in noncoding transcripts between higher and lower organ-
isms.20 Many of these noncoding transcripts are processed to
generate small noncoding RNA such as miRNA, or lncRNA.
Through their interaction with DNA, RNA and proteins non-
coding RNA have emerged as key regulators of gene expression
under both physiological and pathological conditions, as detailed
below. Interestingly, cross-regulatory networks between miRNAs
and lncRNA have recently been identified.21 A number of
detailed sequencing studies have revealed that lncRNA are prefer-
entially expressed in a tissue-specific manner, suggesting that they
Figure 1 Vascular injury initiating factors. Vascular injury is a multicomponent condition resulting from a plethora of initiating factors, such as sheer
stress, endothelial denudation caused by stent deployment, and smoke toxins. This leads to alterations in endothelial function such as a reduction in
antithrombotic agents such as nitric oxide (NO) and prostaglandins, initiation of inflammatory signaling cascades, upregulation of adhesion molecules,
an increase in reactive oxygen species (ROS), and decreased barrier function. Downward arrows indicate the initiating factors causing endothelial injury
while the upward arrows indicate the vascular disease or complication resulting from the initiating factor. Ultimately, changes in endothelial function and
release of inflammatory stimuli and growth factors from inflammatory cells impairs the function of the underlying vascular smooth muscle cells causing
increased proliferation and migration in response to injury.
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hold great promise as selective targets in disease.22 The presence
of lncRNA selective expression in cells and tissues highlights a
potentially novel therapeutic route for controlling disease
pathways.
MicroRNA BIOSYNTHESIS AND FUNCTION
MiRNAs belong to a class of small (18–22 nucleotide, nt),
endogenous noncoding RNA molecules that negatively regulate
gene expression by targeting specific messenger RNAs, thereby
inducing their degradation or translational repression.23 MiRNAs
are generated via a highly controlled and regulated pathway, as
shown in Figure 2. This pathway involves two processing events
that lead to mature miRNA formation. First, primary miRNAs
(pri-miRNAs) are transcribed by RNA polymerase II and proc-
essed in the nucleus through activity of DROSHA into precursor
miRNAs (pre-miRNAs) that are then transported into the cyto-
plasm, via exportin 5. This double-stranded 60–90 nt miRNA
precursor forms the classical stem and loop structure, as shown in
the cytoplasm of Figure 2. In the cytoplasm, pre-miR-s are
cleaved by DICER into a mature RNA duplex that associates
with argonaute proteins that load specific miRNA strands into
the RNA-induced silencing complex24 to form a RISC-miRNA
complex that subsequently represses mRNA transcription or
enhances mRNA degradation.
lncRNA BIOSYNTHESIS AND FUNCTION
lncRNAs are a large family of transcribed RNA molecules with a
length of more than 200 nt with little or no known protein cod-
ing potential. lncRNAs are transcribed throughout the genome
and display remarkable similarity to classical mRNA in that they
are translated by RNA polymerase II and are generally, but not
always, alternatively spliced and polyadenylated.25 They are
highly versatile and function to regulate gene expression by
diverse mechanisms. lncRNA can partially basepair with DNA or
RNA in a sequence-specific manner, or form complexes with pro-
teins. Recent attempts have been made to categorize the various
types of molecular mechanisms involved in lncRNA function. As
such, lncRNA may be defined by four different archetypes (Fig-
ure 3). Archetype 1: signal archetype meaning that the lncRNA
functions as a molecular signal or indicators of transcriptional
activity. Archetype 2: Decoy archetype: lncRNA can bind to and
titrate away other regulatory RNA or proteins. Achetype 3:
Guide archetype: lncRNA direct the localization of specific ribo-
nucleotide proteins to their specific targets. Finally, archetype 4:
Scaffold archetype: lncRNA can act as a structural platform upon
which relevant components may act to stabilize nuclear structures
or signaling complexes.26
MECHANISM OF lncRNA-MiRNA INTERACTIONS
Recent studies have identified that lncRNA can bind to miRNA
in order to “communicate” with other RNA targets.27 An abun-
dance of lncRNA have been shown to be regulated by miRNA
and the reciprocal. Since many of these control important physio-
logical functions, the abundance and binding of each miRNA
and lncRNA will directly alter cellular function.
By sharing common miRNA binding sites with mRNA targets,
lncRNA can sequester and compete with miRNA to prevent
miRNA function and alleviate mRNA repression (Figure 4a).28
Interestingly, 40% of miRNA are found in introns of protein
coding genes.29 Subsequent analysis has shown that 10% of
lncRNA genes also host an miRNA, either in an intron or
exon30 (Figure 4b). Finally, miRNAs have been shown to bind
Figure 2 Basic miRNA processing pathway. MiRNA are transcribed from
DNA and are cleaved into pre-miRs via the actions of DROSHA. Pre-miRs
are then exported into the cytoplasm via exportin-5 and processed into
mature miRNA via the actions of DICER. Following their processing the
mature miRNA will then associate with a complex called RNA induced
silencing complex (RISC) to induce either translational repression or
mRNA degradation. Adapted from Ref. 67.
Figure 3 Schematic diagram of four archetypes of lncRNA mechanisms.
lncRNA can exert their function through complementary binding to RNA,
DNA, and protein molecules. Adapted from Ref. 26. (a) lncRNA may act as
signals of transcriptional activity and may indicate gene regulation.
(b) lncRNA may act as endogenous sponges for molecules such as miRNA,
thus reducing the bioavailability of the molecule, altering cellular function.
(c) lncRNAs can act as guides and tethers for chromatin-modifying com-
plexes, thus aiding in the recruitment to DNA and contributing to tissue-
specific gene expression. (d) lncRNA may act as scaffolds bridging essen-
tial proteins required for gene or cellular regulation.
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to lncRNA, with the addition of other RNA binding proteins,
to regulate lncRNA stability and miRNA-mediated decay
(Figure 4c). In this review, we describe and discuss lncRNA-
miRNA networks in both endothelial and smooth muscle cells
during vascular disease. An overview of novel lncRNA and
miRNA interactions are shown in Figure 5.
TGFb2-OT1 AND MiR-3960, MiR-4488, AND MiR-4459
Transforming growth factor beta 2 overlapping transcript 1
(TGFb2-OT1) is a recently identified lncRNA derived from the
30UTR (untranslated region) of TGFb2. TGFb2-OT1 expres-
sion is regulated through lipopolysaccharide31 and oxidized low-
density lipoprotein, the central mediator involved in the initi-
ation and progression of atherosclerosis. Microarray profiling fol-
lowing TGFb2-OT1 overexpression revealed that TGFb2-OT1
regulated the expression of three miRNAs (miR-3960, miR-
4488, and miR-4459). Subsequent interrogation revealed that
TGFb2-OT1 acts as an endogenous competing RNA bound to
miRNAs (Figure 3a). Furthermore, overexpression of miR-3960,
miR-4488, and miR-4459 resulted in a repression of their down-
stream targets CERS1 (ceramide synthase 1), NAT8L (N-acetyl-
transferase 8-like), and LARP1 (La ribonucleoprotein domain
family, member 1).32 Intriguingly, all three targets are involved in
endothelial cell autophagy and inflammation, central processes
involved in endothelial injury.
In addition, an increase in miR-3960 expression is associated
with areas of increased arterial calcification, which is a hallmark of
advanced atherosclerosis and plaque stability. Intriguingly, both
TGFb and bone morphogenic protein (BMP) play a fundamental
role in vascular remodeling and calcification. Activation of these
signaling molecules triggers several diverse downstream pathways,
including activation of the RUNX2 transcription factor, an essen-
tial and sufficient regulator of vascular calcification.33 Furthermore,
MiR-3960 expression has been shown to be induced by activation
of this osteogenic transcription factor. Additionally, overexpression
of miR-3960 elevated the expression of the osteoblast differentiation
markers alkaline phosphatase (ALP), osteocalcin, and RUNX2, thus
promoting vascular calcification.34 Taken together, these results
Figure 4 lncRNA: miRNA-mediated interactions. Schematic diagram highlighting the routes via which lncRNA and miRNA may interact. (a) lncRNA-miRNA
sponge: binds and sequesters miRNA away from their site of action, thus reducing their function within the cell. (b) lncRNA generating miRNA. lncRNA
may host miRNA both within their exons and introns. (c) Some lncRNA are degraded by miRNA.
Figure 5 Overview of lncRNA-mediated interactions in vascular smooth
muscle and endothelial cells during vascular disease. Many novel lncRNA
have been identified to bind and regulated miRNA function. Outside labels
indicate the lncRNA involved in the interaction. Inner ring highlights the
miRNA associated with the interacting lncRNA.
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suggest that overexpression of TGFb2-OT1, and subsequent down-
regulation of miR-3960, may prove a novel way to specifically target
RUNX2 signaling in the setting of atherosclerosis and vascular
calcification.
Lnc362 AND MiR-221 AND MiR-222
Aberrant regulation of angiotensin II (Ang II) has been linked to
hypertension and atherosclerosis.35 Following RNA-sequencing
in Ang II-treated cells, Leung et al. identified a collection of Ang
II-responsive lncRNA. Among these, lncRNA 362 was identi-
fied.36 lncRNA 362 is located proximal to two miRNA, miR-221
and miR-222, which have been linked with regulation of SMC
proliferation via suppression of c-kit and p27kip.37,38 Knock-
down of lncRNA 362 is associated with a reduction in SMC pro-
liferation and expression levels of these miRNAs, indicating that
these miRNAs are coregulated with lncRNA-362. Furthermore,
specific manipulation of either miRNA has been shown to reduce
neointimal formation associated with smooth muscle cell prolif-
eration.37 In accordance with this study, Bazan et al. identified
that miR-221 and miR-222 were significantly downregulated in
the shoulder region of atherosclerotic plaques. Atherosclerotic
plaque vulnerability is accompanied by changes in the molecular
and cellular function in the plaque shoulder, including a decrease
in VSMC proliferation. This reduction in miR-221/miR-222
promotes the formation of an unstable plaque via decreased
p27Kip1 mRNA expression, as described above, encouraging pla-
que rupture.39
Atherosclerosis initiation is linked to vascular endothelial
injury and subsequent recruitment of leukocytes to activated
endothelial cells.40 It has been previously demonstrated that miR-
221/222 can inhibit tube formation, migration, and wound heal-
ing by directly targeting c-Kit. Zhu et al. have shown overexpres-
sion of miR-221/222 in HUVECs downregulates key adhesion
molecules on vascular endothelial cells, thus altering inflamma-
tory pathways involved in atherosclerosis initiation.41
These studies raise the intriguing possibility that modulation
of lncRNA could provide a novel mechanism to attenuate the
hyperproliferative effects of Ang II within multiple vascular path-
ologies, including coronary artery disease, PAH, and atherosclero-
sis since both these miRNAs are implicated in proliferative
vascular remodeling.
Linc MD1 AND MiR-206, MiR-133B, AND MiR-135
Unlike miRNA, lncRNA are not confined to a single mechanism
of action. One example of this is Linc-MD1, a muscle-specific
lncRNA with two distinct mechanisms of action for controlling
physiology. As shown in Figure 4b, some lncRNA are processed
to generate miRNA. Linc-MD1 generates miR-206, in one
intron, and miR-133b, in one exon.42 MiR-206 has previously
been linked to vascular remodeling during pulmonary arterial
hypertension. These studies demonstrated that miR-206 expres-
sion is associated with increased right ventricular systolic pres-
sure.43 Reduction in levels of miR-206 resulted in increased levels
of smooth muscle cell differentiation markers, a-smooth muscle
actin and calponin, implicating its importance in the differentia-
tion of SMCs. In addition, miR-206 overexpression results in a
composite downregulated of Notch 3 expression, a key mediator
in PAH development. Taken together, these studies suggest that
miR-206 regulates vascular remodeling in the setting of pulmo-
nary hypertension via a number of different mechanisms, which
play a prominent role in disease pathology (smooth muscle cell
proliferation, apoptosis, and differentiation), suggesting that it
may have an enhanced therapeutic efficacy of pulmonary arterial
SMC.
Although no direct link between PAH and miR-133b has been
established in the lung, miR-133b has been implicated as a bio-
marker of right ventricle hypertrophy and therefore a biomarker
of PAH.44
Additionally, Linc-MD1 also contains binding sites for miR-
135 and miR-133, thus Linc-MD1 can not only produce miR-
133 but can also control its function via acting as a sponge for its
own produced miRNA. Unlike lncRNA that regulate gene
expression at the epigenetic level, Linc-MD1 is located solely in
the cytoplasm of cells. In addition to its role in pulmonary arte-
rial hypertension, miR-133b has been shown to be involved in
vascular calcification. In vitro and in vivo vascular calcification
models identified miR-133b as being significantly downregulated,
while miR-133b target RUNX2, as mentioned above, was signifi-
cantly elevated. Additionally, the expression of several inhibitors
of vascular calcification were reduced in both in vitro and in vivo
models.45 In accordance with this study, Cipollone et al. showed
an increase in miR-133 expression in symptomatic compared to
asymptomatic carotid plaques.46 Thus, modulation of Linc-MD1
may prove beneficial in the pathogenesis of other vascular pathol-
ogies, such as atherosclerosis.
H19 AND MiR-LET-7
H19 is an lncRNA conserved across humans and rodents. Abun-
dantly expressed in human muscle, the aberrantly expressed
lncRNA, H19, has been implicated in several genetic condi-
tions.47 Recently, the functional role of H19 had remained
unknown, until Kallen et al. discovered that H19 harbors both
canonical and noncanonical binding sites for the let-7 family of
miRNAs.48 Utilizing both knockdown and overexpression to
modulate H19 expression, the authors discovered that H19 mod-
ulates let-7 availability by acting as a “molecular sponge,” reduc-
ing the level of free let-7 able to bind its target mRNA.
Physiologically, this has implications in the control of the SMC
phenotype, where knockdown of H19 caused precocious muscle
differentiation, a phenotype recapitulated by let-7 overexpression.
Additionally, the role of lncRNA H19 has been assessed in rats
in vivo. H19 was undetectable in uninjured carotid arteries; how-
ever, 7 and 14 days postinjury, H19 was abundantly expressed
and localized to the neointimal area following in situ analysis.
Intriguingly, H19 was initially identified as a developmental
lncRNA, known to be expressed during development and down-
regulated after birth.49 This highlights the notion that the vascu-
lar response to injury is accompanied by the reexpression of
several fetal gene networks.50
H19 lncRNA is a primary precursor for miR-675, located in
the first exon. Although known to act as an effective biomarker
in heart failure patients,51 and to reduce proliferation of a range
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of embryonic cell lines,52 no link between miR-675 and vascular
endothelial or smooth muscle cells has been identified. This may
provide an interesting avenue for further investigation.
Linc-P21 AND MiR-LET-7 AND MiR-130b
Unlike miRNA, lncRNA are not as well conserved. A recent
report suggests that up to 44% of lncRNA may be conserved
between mammals22; however, others show the number to be
much lower.53 One such conserved lncRNA is LincRNA-p21, a
novel lncRNA located 15kb upstream of the cell cycle regulator
gene p21. Linc-p21 is 3 kbp in length and has been shown to
promote cell proliferation, apoptosis, and DNA damage response
in a variety of disease states.54
Unlike the more conserved miRNA, lncRNA can have multi-
ple mechanisms of action. One example of this is the long non-
coding RNA Linc-p21. Linc-p21 is a transcriptional target of
p53, a tumor suppressor that regulates cell cycle. The expression
of Linc-p21 is dramatically downregulated in atherosclerotic
lesion from mice maintained on an atherogenic background. Sub-
sequent gain- and loss-of-function studies revealed that loss of
Linc-p21 expression is associated with an increase in SMC prolif-
eration and reduction in apoptosis in vascular smooth muscle
cells. Furthermore, lentiviral-mediated knockdown of Linc-p21
expression enhanced neointimal formation in murine arteries
subjected to wire injury, events associated with increased SMC
proliferation and survival. Genome-wide analysis revealed that
LincRNA-p21 inhibition dysregulated many p53 targets. This
study was one of the first to demonstrate that modulation of
lncRNA has therapeutic potential in the setting of acute vascular
injury.
In addition to lncRNA controlling miRNA expression and
function, miRNA can also regulate lncRNA expression via
binding and altering lncRNA function. Recently, PAR-CLIP
(photoactivatable ribonucleoside-enhanced crosslinking and
immunoprecipitation) analysis revealed that the RNA binding
protein (RBP) HuR associates with several lncRNAs. HuR is a
ubiquitous RBP that induces cellular proliferation, apoptosis, and
cellular immune responses. HuR performs most of these activities
via binding and regulating target RNA stability. Interestingly,
Yoon et al. identified that binding of both HuR and miRNA let-
7 decreased Linc-p21 stability, leading to its degradation and loss
of function, an effect common with miRNA on mRNA55
(Figure 4c). Additionally, linc-p21 has also been shown to act as
an endogenous sponge to miRNA-130b in both vascular endo-
thelial and smooth muscle cells. MiR-130b has been implicated
in both endothelial cell and smooth muscle cell pathology.
In endothelial cells, miR-130 modulated apelin-miR-424/
503-FGF2 signaling, while in smooth muscle cells miR-130
modulated STAT3-miR-204 signaling to promote PAH-
associated phenotypes.56
NFIA-AS1 AND MiR-382-5p
As mentioned previously, smooth muscle and endothelial cells
are not the only cell types to play a prominent role in vascular
disease. Via microarray techniques, Hu et al.57 discovered that
lncRNA NFIA-AS1 expression was upregulated, whereas nuclear
factor IA (NFIA) expression was downregulated in a human
THP-1 foam cell model. As it has been previously shown that
lncRNA can affect target genes, the authors assessed known
NFIA-regulated miRNA. The data suggest that NFIA-AS1 does
not bind directly to miR-382-5p but acts as an enhancer via some
additional mechanism to promote the expression of this miRNA.
These data were also confirmed through subsequent knockdown
of this lncRNA in vitro. In a mouse model, lentiviral-mediated
overexpression of this lncRNA affected central mechanisms of
atherogeneisis such as the ratio of high-density lipoprotein
(HDL) to low-density lipoprotein (LDL) in the circulation,
increased HDL cholesterol, reduced LDL cholesterol, and
decreased circulation of inflammatory cytokines, IL-1b, IL-6,
TNF-a, and C-reactive protein (CRP). Overexpression also
reduced atherosclerosis in apolipoprotein E-deficient (Apoe–/–)
mice.57 In humans the NFIA gene locus has not been associated
with atherosclerosis to date, nor has miR-382-5p been investi-
gated in atherosclerosis or any other vascular disease. However,
this article highlights lncRNA as master regulators of disease and
may highlight NFIA-AS1 as an important target for atherosclero-
sis treatment.
CLINICAL UTILITY OF lncRNA
lncRNA as diagnostic biomarkers
For clinical medicine, lncRNA offer many benefits. lncRNA typ-
ically show tissue-restricted and vascular disease-restricted pat-
terns of expression.58,59 Given this specificity, lncRNA may be
superior biomarkers than current protein coding genes for cardio-
vascular disease. Additionally, lncRNA in themselves are func-
tional molecules, thus their expression may be a better indicator
of disease states.60
One prominent example is CoroMarker (AC100865.1), a
lncRNA that is markedly overexpressed in coronary artery disease
(CAD). The authors identified CAD biomarkers using the strict
criteria of signal intensity 8, fold change >2.5, and P < 0.005.
The predictive value of CoroMarker was assessed in a large
cohort with 221 CAD patients and 187 control individuals.
CoroMarker was able to successfully identify 78.05% of CAD
patients.61 CoroMarker is stably expressed within the plasma and
further tests to evaluate its ability to detect CAD are currently
underway.
lncRNA as therapeutics
The transition from lncRNA biomarkers to lncRNA therapeutics
is also showing promising advances. Companies and organiza-
tions such as Miragen Therapeutics and Regulus are developing
ncRNA-based strategies against cancer, cardiovascular, and neuro-
logical diseases. Although lncRNA clinical trials are still several
years away, it is generally accepted that targeting of lncRNA ther-
apeutically may lead to less off-target effects, due to their
enhanced tissue specificity and their ability to modulate miRNA/
mRNA networks. Additionally, the advantage of using RNA as a
therapeutic medium would allow quick regulatory functions to
be altered without the need for protein translation. One such
noncoding RNA therapeutic, miravirsen, is currently in phase II
clinical trials for the treatment of hepatitis C. Miravirsen is an
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inhibitor of miR-122, a liver-specific miRNA that the hepatitis C
virus requires for replication. Miravirsen is designed to sequester
miR-122, making it unavailable to the hepatitis C virus.62 This
highlights one mechanism by which noncoding RNA can be modu-
lated; however, there are several other therapeutic approaches for
targeting lncRNA in man:
1. Therapeutic silencing of lncRNA. lncRNA expression can be
altered through the use of RNAi technology. Therapeutic RNAi
technology has now been tested in several mammals including
man.63,64 Current clinical trials are investigating the safety and
efficacy of RNAi-mediated therapeutics and it could be relatively
easily adapted to allow RNAi therapies targeting lncRNA.
2. Functional block of lncRNA. This could be achieved through
the utilization of small molecules that block binding sites on
protein interacting partners or oligonucleotides that bind to the
ncRNA, blocking the interaction with partners such as miRNA,
while allowing the lncRNA to bind additional partners at other
sites not associated with disease. Current research has already
assessed the use of high-throughput screening to identify small
molecule disruptors for the lncRNA HOTAIR.65
3. Structure disruption. Small molecules can be utilized to bind
to the lncRNA of interest and disrupt its secondary structure,
thus disrupting the binding site on the lncRNA or small mole-
cules can be utilized to mimic the structure of the lncRNA,
thus competing with the lncRNA for target sites. Research is
underway to achieve this goal.60,66
4. Finally, gene therapy could be utilized to deliver beneficial
lncRNA.
Due to their multiple functional roles, the therapeutic poten-
tial of lncRNA is extremely vast. Ultimately, further analysis of
lncRNA structure and functional roles will be expected before
these therapeutic options can be used routinely.
CONCLUSION
Exploring the transcriptome that controls SMC and EC pheno-
type is of key importance in unraveling the regulatory pathways
and disease mechanisms of vascular pathology. Greater under-
standing of the complex interplay between RNA and protein
coding genes will undoubtedly present new therapeutic applica-
tions and diagnostic implications in vascular pathology.
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